TABLE I.
Immune checkpoint inhibitors assessed by the pan-Canadian Oncology Drug Review
| Drug and tumour type | Stage | Indication | Implementation | Biomarker details |
|---|---|---|---|---|
| Atezolizumab | ||||
| NSCLC | IV | Second line | 6 Jul 2018 | — |
| SCLC | Extensive | First line | 14 Feb 2020 | — |
|
| ||||
| Durvalumab | ||||
| NSCLC | III | Consolidative | 21 May 2019 | — |
|
| ||||
| Ipilimumab | ||||
| Melanoma | Advanced | First line | 14 Jan 2015 | — |
| Second line | 2 May 2012 | — | ||
|
| ||||
| Nivolumab | ||||
| Melanoma | Advanced | First line | 18 Apr 2016 | — |
| Node-positive | Adjuvant | 22 Mar 2019 | — | |
| NSCLC | IV | Second line | 20 Jun 2016 | — |
| Renal cell carcinoma | IV | Second line | 19 Sep 2016 | — |
| HNSCC | IV | Second line | 18 Sep 2017 | — |
| Hodgkin lymphoma | — | Failed ASCT | 18 May 2018 | — |
|
| ||||
| Ipilimumab–nivolumab | ||||
| Melanoma | Advanced | First line | 15 Dec 2017 | — |
| Renal cell carcinoma | IV | First line | 16 Nov 2018 | — |
|
| ||||
| Pembrolizumab | ||||
| Melanoma | Advanced | First line | 1 Dec 2015 | — |
| III | Adjuvant | 19 Aug 2019 | — | |
| NSCLC | IV | First line | 8 Sep 2017 | PD-L1 TPS ≥50% |
| First linea | 17 Jun 2019 | — | ||
| First lineb | 20 Jan 2020 | — | ||
| Second line | 18 November 2016 | PD-L1 TPS ≥1% | ||
| Hodgkin lymphoma | — | Relapsed | 22 Jan 2018 | — |
| Urothelial carcinoma | IV | First line | 21 Oct 2019 | PD-L1 CPS ≥10% |
| Second line | 19 Mar 2018 | — | ||
a
Nonsquamous histology.
b
Squamous histology.
NSCLC = non-small-cell lung cancer; SCLC = small-cell lung cancer; HNSCC = head and neck squamous-cell carcinoma; ASCT = autologous stem-cell transplantation; TPS = tumour proportion score; CPS = combined positive score.